名稱 | ADCP Bioassay Effector Cell FcγRIIa (H variant)-NF |
型號(hào) | CBP74106 |
報(bào)價(jià) | ![]() |
特點(diǎn) | ADCP Bioassay Effector Cell FcγRIIa (H variant)-NFAT/Jurkat,母細(xì)胞:Jurkat,凍存條件:90% FBS+10% DMSO |
產(chǎn)品搜索
相關(guān)文章
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株 > CBP74106ADCP Bioassay Effector Cell FcγRIIa (H variant)-NF

- 詳細(xì)內(nèi)容
I. Background | |
ADCP(Antibody dependent cellular phagocytosis)是抗體依賴性細(xì)胞介導(dǎo)的吞噬作用。 是一種免疫消除機(jī)制,其憑借單克隆抗體(mAb)靶向腫瘤細(xì)胞,以促進(jìn)吞噬免疫細(xì)胞將 腫瘤細(xì)胞從體內(nèi)清除。ADCP 由單核細(xì)胞、巨噬細(xì)胞、嗜中性粒細(xì)胞和樹(shù)突細(xì)胞通過(guò)表達(dá) FcγRIIa(CD32a)、FcγRI(CD64)和 FcγRIIIa(CD16a)來(lái)介導(dǎo)來(lái)吞噬疾病細(xì)胞,研究表 明 FcγRIIa 是參與該過(guò)程的 FcγR 受體。 | |
II. Description | |
ADCP Bioassay Effector Cell FcγRIIa(H variant) -NFAT Jurkat 報(bào)告基因藥靶模型很好的 模擬了體內(nèi) ADCP 的信號(hào)轉(zhuǎn)導(dǎo)過(guò)程,原理見(jiàn)下圖所示。
Figure 1. ADCP Bioassay Effector Cell FcγRIIa(H variant) -NFAT Jurkat 細(xì)胞模型原理圖 | |
III. Introduction | |
Host Cell: | Jurkat |
Expressed gene: | FcγRIIa (H variant)-NFAT |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | RPMI-1640+10%FBS+1 μg/ml Puromycin+400 μg/ml Hygromycin B |
Storage: | Liquid nitrogen |
Application(s): | Functional(Report Gene) Assay |
IV. Description of Host Cell Line | |
Organism: | Human |
Tissue: | Peripheral blood |
Disease: | Childhood T acute lymphoblastic leukemia |
Morphology: | Lymphoblast |
Growth Properties: | Suspension |
Ⅴ. Representative Data | |
Figure 2. Dose Response of Rituximab in ADCP Bioassay Effector Cell FcγRlla (H variant) -NFAT Jurkat (C2) with Raji. |